Taienkang (301263.SZ): Application for registration and marketing license for drugs produced in China was accepted

Zhitong Finance App News, Taiencang (301263.SZ) announced that Anhui Taienkang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Notice of Acceptance” of the application for registration and marketing of drugs produced domestically issued by the State Drug Administration. The State Drug Administration examined the drug registration and marketing license application for the above drugs and decided to accept it.

According to the announcement, indobufen tablets are a platelet aggregation inhibitor. It reduces the risk of blood clots by reversibly inhibiting cyclooxygenase and various inducers, and is used for ischemic cardiovascular disease, ischemic cerebrovascular disease, and venous thrombosis caused by arteriosclerosis. It can also be used to prevent thrombosis during hemodialysis.